Chemotherapy and chemoimmunotherapy outcomes in gastric MALT lymphoma
| Study . | Patients . | Early stage, % . | Treatment . | Outcomes, % . |
|---|---|---|---|---|
| Hammel et al23 | 24 | 71 | Cyclophosphamide or chlorambucil | 75 CR |
| Avilés et al24 | 83 | 100 | CHOP×3 + CVP×4 | 100 CR |
| Jäger et al25 | 19 | 100 | Cladribine | 100 CR |
| Salar et al26 | 21 | 64 | Bendamustine+rituximab | 94 CR; 6 PR |
| Zucca et al17 | 53 | — | Rituximab+chlorambucil | 91 CR |
| 57 | — | Chlorambucil | 61 CR | |
| 61 | — | Rituximab | 67 CR |
| Study . | Patients . | Early stage, % . | Treatment . | Outcomes, % . |
|---|---|---|---|---|
| Hammel et al23 | 24 | 71 | Cyclophosphamide or chlorambucil | 75 CR |
| Avilés et al24 | 83 | 100 | CHOP×3 + CVP×4 | 100 CR |
| Jäger et al25 | 19 | 100 | Cladribine | 100 CR |
| Salar et al26 | 21 | 64 | Bendamustine+rituximab | 94 CR; 6 PR |
| Zucca et al17 | 53 | — | Rituximab+chlorambucil | 91 CR |
| 57 | — | Chlorambucil | 61 CR | |
| 61 | — | Rituximab | 67 CR |